摘要
目的探讨雷贝拉唑联合托烷司琼及地塞米松防治肿瘤患者化疗所致消化道反应的疗效。方法选取2014年2—7月,在中国医学科学院北京协和医学院肿瘤医院门诊化疗的非胃肠道恶性肿瘤患者120例为研究对象。采用随机数字表法将患者分为试验组和对照组各60例,化疗前后及化疗过程中,试验组给予雷贝拉唑+托烷司琼+地塞米松治疗,对照组给予奥美拉唑+托烷司琼+地塞米松治疗,化疗两个周期后(每个周期为21 d)比较两组患者的疗效。结果试验组在抑制恶心、呕吐、反酸及改善食欲、生活质量的疗效上均优于对照组,差异有统计学意义(u值分别为-2.199、-2.178、-2.089、-2.283、-2.062,P<0.05);且在临床总疗效上亦优于对照组,差异有统计学意义(u=2.137,P<0.05)。结论雷贝拉唑联合托烷司琼及地塞米松防治化疗药物所致胃肠道反应疗效较好,可作为新一代强效止吐方案,值得临床关注及应用。
Objective To explore the efficacy of rabeprazole combined with tropisetron and dexamethasone in the prevention and treatment of gastrointestinal reaction in cancer patients undergoing chemotherapy .Methods We enrolled 120 patients with non-gastrointestinal malignant tumor who received chemotherapy in the outpatient department of the Tumor Hospital of Peking Union Medical College of Chinese Academy of Medical Sciences from February to July , 2014.The patients were divided into two groups: trial group (n=60) and control group (n=60) .Before, after and amid chemotherapy, the trial group was given rabeprazole+tropisetron+dexamethasone , and the control group was given omeprazole +tropisetron+dexamethasone .After two cycles following chemotherapy (one cycle is 21 days), comparison was made between the two groups in efficacy .Results The trial group was superior than the control group in the efficacy regarding the control of nausea , vomiting and sour regurgitation and the improvement of appetite and quality of life (u=-2.199, -2.178, -2.089, -2.283, -2.062; P〈0.05); the trial group was better than the control group in general clinical efficacy (u=2.137, P〈0.05) .Gonclusion The application of rabeprazole combined with tropisetron and dexamethasone has good efficacy in the prevention and treatment of gastrointestinal reaction induced by chemotherapy .It can be used as a new effective regimen in controlling vomiting , and it should be attached more importance and put into wider application .
出处
《中国全科医学》
CAS
CSCD
北大核心
2015年第22期2688-2691,共4页
Chinese General Practice
关键词
肿瘤
化学疗法
辅助
胃肠道
雷贝拉唑
奥美拉唑
托烷司琼
地塞米松
治疗结果
Neoplasms
Chemotherapy,adjuvant
Gastrointestinal tract
Rabeprazole
Omeprazole
Tropisetron
Dexamethasone
Treatment outcome